Company: FTII
Filing Date: 2025-04-09
Form Type: 10-K
Source: 0001641172-25-003384
Chunk: 856

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-04-09
Form: 10-K
Item: Item 2
Chunk 856
---
 approval from FINRA to begin trading over the counter with the symbols “FTII” “FTIIU” and “FTIIW”
commencing on February 26, 2025.

21

The
Company expects that Nasdaq will file a Form 25-NSE with the SEC to delist its securities, and that the delisting will become effective
ten (10) days after Nasdaq files the Form 25-NSE with the SEC to complete the delisting. The Company does not intend to file a Form 15
with the SEC to terminate the registration of its securities under the Securities Exchange Act of 1934, as amended, and expects that
the Company’s securities will be quoted on the over-the-counter market. In addition, as disclosed in the Registration/Proxy Statement
on Form S-4 filed with the SEC on February 14, 2025, the Company intends to make a listing application for the securities of the combined
company to be traded on Nasdaq.

Claw-back
of First Extension Overpayment Amount and Second Extension Overpayment Amount

On
or about March 6, 2025, the Trustee of the Trust Account commenced the claw-back process in connection with the First Extension Overpayment
Amount and Second Extension Overpayment Amount. As of March 31, 2025, approximately $337,442 in aggregate have been received in connection with
the First Extension Overpayment Amount, and $176,184 in aggregate have been received in connection with the Second Extension Overpayment
Amount.

Satisfaction
and Discharge Agreement with the Underwriter

On February 6, 2025, the Company and Longevity executed a Satisfaction
and Discharge of Indebtedness Pursuant to Underwriting Agreement dated February 15, 2022 (the “Discharge Agreement”) with
D. Boral Capital LLC (f/k/a EF Hutton LLC, division of Benchmark Investments, LLC) (the “Underwriter”). Pursuant to the Underwriting
Agreement in relation to the IPO, upon the completion of an initial business combination, the Underwriter is entitled to a deferred underwriting
commission of $3,450,000 (“Deferred Commission”). Under the Discharge Agreement, instead of receiving the full Deferred
Commission in cash at the closing of the business combination with Longevity and other parties thereto, the Underwriter will accept (1)
$500,000 in cash at the time of the closing; (2) a $1,475